Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
- 1 February 2020
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 126, 65-73
Abstract
No abstract availableKeywords
Funding Information
- Les amis de l'Institut Bordet (2018-02)
- AstraZeneca
- Novartis
- Roche
- Genentech
- AstraZeneca
- Lilly
- MSD
- Novartis
- Pfizer
- Genentech
- Servier
- Roche
- Novartis
- GSK
- Roche
- Genentech
- Roche
- Genentech
- AstraZeneca
- GSK
- Novartis
- Servier
This publication has 22 references indexed in Scilit:
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Annals of Oncology, 2013
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2013
- Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trialsCancer Treatment Reviews, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2012
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and CapecitabineJournal of Clinical Oncology, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive CancerClinical Cancer Research, 2011
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed TherapyJournal of Clinical Oncology, 2011
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast CancerJournal of Clinical Oncology, 2010